Article Text

Download PDFPDF
Do we know when to treat neonatal thrombocytopaenia?
  1. Vidheya Venkatesh1,
  2. Anna E Curley1,
  3. Paul Clarke2,
  4. Timothy Watts3,
  5. Simon J Stanworth4
  1. 1Neonatal Intensive Care Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  2. 2Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
  3. 3Neonatal Intensive Care Unit, Guys and St Thomas NHS Foundation Trust, London, UK
  4. 4Department of Haematology, National Health Service Blood and Transplant/Oxford University Hospitals Trust, Oxford, UK
  1. Correspondence to Dr Simon J Stanworth, Department of Haematology/Transfusion Medicine, NHS Blood & Transplant/Oxford University Hospitals NHS Trust, University of Oxford, Level 2, John Radcliffe Hospital, Headington, Oxford OX3 9BQ, UK; simon.stanworth{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Thrombocytopaenia is highly prevalent in neonatology affecting around 25% (22–35%) of all neonates admitted to neonatal intensive care units.1 Clinical signs of bleeding are also commonly documented in preterm neonates. But the close temporal association commonly noted in sick babies between low platelet counts and the occurrence of bleeding does not establish cause and effect. Thrombocytopaenia is a risk factor for poorer neonatal outcomes, although it is unclear whether it is largely a marker of severity of illness and comorbidity.2 Platelet transfusion remains the only readily available specific treatment for this condition. Decisions about when to treat thrombocytopaenia are therefore linked to defining safe and effective platelet transfusion practices.

Platelet transfusion practice

Policies for neonatal platelet transfusion therapy vary widely between clinicians, institutions and countries, and are inevitably based on specified threshold counts of platelets, although platelet counts provide no information on changes in platelet function. Alternative criterion of the need for platelet transfusions, such as platelet mass (which is based on a sum of platelet count and platelet volume, based on the rationale that larger platelets may be more effective haemostatically), have been proposed, but larger studies to assess clinical outcomes have not been undertaken.3

A large web based survey of neonatologists in Canada and USA reported significant variation between neonates units and indicated that platelet transfusions were frequently administered to non-bleeding neonates with platelet counts >50×109/l.4 In the UK, a telephone survey of all tertiary level neonatal units demonstrated similar variation in practice but with the most common thresholds for transfusion in well or stable term and preterm infants being 25×109 and 30×109/l, respectively.5

Bleeding and thrombocytopaenia

It should be stressed that the safety and efficacy of these platelet count thresholds for prophylactic platelet transfusions have never been assessed in randomised trials.6 Murray …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.